• Publications
  • Influence
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of patients respond well to current therapy and have prolonged survival,Expand
  • 9,002
  • 430
  • PDF
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
A role for B-cell-receptor (BCR) signalling in lymphomagenesis has been inferred by studying immunoglobulin genes in human lymphomas and by engineering mouse models, but genetic and functionalExpand
  • 1,203
  • 106
  • PDF
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
BACKGROUND The survival of patients with diffuse large-B-cell lymphoma after chemotherapy is influenced by molecular features of the tumors. We used the gene-expression profiles of these lymphomas toExpand
  • 2,442
  • 103
Stromal gene signatures in large-B-cell lymphomas.
BACKGROUND The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or R-CHOP, has significantly improved the survival of patientsExpand
  • 1,366
  • 91
  • PDF
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
The two major subtypes of diffuse large B cell lymphoma (DLBCL)—activated B cell–like (ABC) and germinal center B cell–like (GCB)—arise by distinct mechanisms, with ABC selectively acquiringExpand
  • 632
  • 56
Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia
The most common human leukemia is B cell chronic lymphocytic leukemia (CLL), a malignancy of mature B cells with a characteristic clinical presentation but a variable clinical course. The rearrangedExpand
  • 1,167
  • 55
  • PDF
Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma
Background Diffuse large B‐cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene‐expression profiling has identified subgroups of DLBCL (activated B‐cell–like [ABC],Expand
  • 493
  • 46
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma
Using current diagnostic criteria, primary mediastinal B cell lymphoma (PMBL) cannot be distinguished from other types of diffuse large B cell lymphoma (DLBCL) reliably. We used gene expressionExpand
  • 986
  • 45
  • PDF
Molecular diagnosis of Burkitt's lymphoma.
BACKGROUND The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma is crucial because these two types of lymphoma require different treatments. We examined whetherExpand
  • 817
  • 44
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.
BACKGROUND Patients with follicular lymphoma may survive for periods of less than 1 year to more than 20 years after diagnosis. We used gene-expression profiles of tumor-biopsy specimens obtained atExpand
  • 1,286
  • 43
  • PDF